- FDA Rules for Cigarettes Are a Victory for Public Health, for Science (and for the Earth’s Climate?)
- Legislation Introduced to Codify Stem Cell Rules
- Commissioner Enhances FDA’s Commitment to Personalized Medicine
- Perfecting Policy on Stem Cells
- NIH and FDA Aim to Retool Regulatory Science
- DOE Leads Federal Funding for a Regional Innovation Cluster
- Certainty on the Science of Climate Change
- They’re Not Perfect Cells, But They’re Model Cells
- Genomic Medicine on the March
- President’s Budget Aims to Recharge Regional Innovation
- Event: The Science of Climate Change
- Progress in Bioethics
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
Chemical Wonders and Dual Use Dangers From Synthetic Biology
Synthetic biology, which involves producing artificial life forms from genomes built on lab benches, promises to unleash a variety of chemical wonders, pose a slate of dual-use dangers, and ignite intellectual property battles over patents for the “software of life.” Rick Weiss provided a whirligig tour of the field and its implications in yesterday’s Washington Post (via the KSJ Tracker).
UC Santa Cruz Chemistry Professor David Deamer offered a brief history of the research and an overview of the science behind the field in a recent Science Progress article. He situates discoveries in synbio with other major scientific advances like semiconductors, penicillin, and atomic energy. In his assessment, the benefits outweigh the risks, and the risks, at the moment, are not significant: “So far, there are virtually no restrictions on this kind of research, nor should there be, in my judgment….The bottom line is that there are always risks associated with every benefit, and that global human society is too complex ever to exert absolute control.”
Weiss catalogs several applications for synthetically engineered organisms. J. Craig Venter proposes to create microbes that directly produce biofuels. LS9 is a San Carlos, CA company currently growing E. coli that processes sugars into liquid fuel. And DuPont uses “semi-synthetic” bacteria to produce PDO, an industrial chemical useful in a variety of applications, including adhesives, laminates, and polyester fibers. A current medical application produces super-efficient bacteria that generate artemisinin, a malaria drug.
If the danger of malevolent synbio projects is indeed manageable, Weiss points to another possible policy concern—the hazard of anti-competitive hegemony in the field:
Some experts are worried that a few maverick companies are already gaining monopoly control over the core ‘operating system’ for artificial life and are poised to become the Microsofts of synthetic biology. That could stifle competition, they say, and place enormous power in a few people’s hands.
This possibility raises the question: can and should the Federal government regulate ownership of the building blocks of life and the tools with which to manipulate them?
Comments on this article


